Gould Capital’s Charles River Laboratories CRL Stock Holding History

Gould Capital’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6	Closed	-$1.2K	–	207
2025 Q4	$1.2K	Sell	6 -27	-82%	-$4.9K	﹤0.01%	185
2025 Q3	$5.16K	Sell	33 -30	-48%	-$4.76K	﹤0.01%	161
2025 Q2	$9.56K	Sell	63 -18	-22%	-$2.4K	0.01%	143
2025 Q1	$12.2K	Sell	81 -5,442	-99%	-$912K	0.01%	124
2024 Q4	$1.02M	Sell	5,523 -694	-11%	-$134K	0.71%	40
2024 Q3	$1.22M	Buy	+6,217	New	+$1.29M	0.81%	36

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Gould Capital's CRL Position: Q1 2026 in Review

Gould Capital sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 6 shares — an estimated $1.2K sold.

Gould Capital first reported a position in CRL in Q3 2024 and held it in 6 quarters. The position peaked at $1.22M in Q3 2024. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Gould Capital reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
Gould Capital sold 6 Charles River Laboratories shares in Q1 2026, an estimated $1.2K.
Gould Capital first reported a position in Charles River Laboratories in Q3 2024 and held it in 6 quarters.
Gould Capital's Charles River Laboratories position peaked at $1.22M in Q3 2024.
557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Gould Capital's 13F filing for Q1 2026, filed 18 May 2026.